A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria(PNH)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is a multicenter, randomized, open-label phase 2 study. Adult Patients with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy were included. Subjects were treated with HSK39297 for 24 weeks.
Epistemonikos ID: 6dd535d8cd48771a14eb6e66c305a33ee8a61390
First added on: Sep 01, 2024